InSilico Medicine Hong Kong Ltd.

NR3C1 encodes the glucocorticoid receptor (GR) and regulates stress responses, metabolism, immune function, and inflammation, making it a promising therapeutic target for cortisol‑excess–related diseases. Empowered by Insilico Medicine’s proprietary Pharma.AI, ISM6200 is a potent selective NR3C1 inhibitor with low drug–drug interaction risk, strong efficacy across multiple animal models, favorable ADME/PK properties, and a low predicted efficacious human dose. ISM6200 also shows dose‑dependent anti‑tumor activity in combination settings; notably, the FDA has approved a clinical proof‑of‑concept study of the NR3C1 inhibitor relacorilant plus nab‑paclitaxel in cancer. In preclinical models, ISM6200 demonstrated superior efficacy in Cushing’s syndrome, hypercortisolism‑associated obesity, and glaucoma. This is the 29th Preclinical/Developmental Candidate (PCC/DC) Nomination by Insilico. Since 2021, 12 PCCs obtained IND clearance, 3 entered Phase II, among which 1 Phase IIa trial is completed, with 10+ business development deals marking superior quality of Insilico PCC and high standards.

AI-powered biotech company Insilico Medicine has signed a deal with pharma giant Eli Lilly and Company that could be worth $2.75 billion, plus tiered royalties on future sales, that allows the pharma giant to exclusively use Insilico's AI engine for drug discovery and development across several therapeutic areas. Insilico's Pharma.AI platform uses generative AI and large language models (LLMs) to speed up drug discovery, scientific research and sustainability. The company touts its platform as an end-to-end tool capable of discovering and designing a small-molecule or biologic drug alongside the biomarker for patient selection. Insilico says on its site that the result can produce a significant disease-modifying or curative response. Under the agreement, Lilly was granted an exclusive global license to use Insilico's AI for the drug development, manufacturing and commercialization of potential therapeutics. The partners will also collaborate on multiple research and development programs by combining Insilico's Pharma.AI platforms with the pharma giant's disease knowledge and development capabilities, with Lilly selecting the focus areas. Per the agreement, Insilico will receive $115 million upfront. Once commercial, development and regulatory milestones are reached, the company can receive up to approximately $2.75 billion, plus royalties on future sales. "From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery. By deploying frontier AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time," Alex Zhavoronkov, founder and CEO of Insilico Medicine, said in a statement. "Working with Lilly, we aim to deliver transformative therapies that treat diseases with high unmet need. This collaboration is a testament to the power of AI in tackling the most complex challenges in human health." ​Insilico has announced numerous partnerships with pharma companies this year. This month, Insilico unveiled an extended partnership with Hong Kong-based Tenacia Biotechnology, a commercial-stage biopharma company focused on developing therapeutics for individuals with neurological disorders. The deal was valued at up to $94.75 million and would deepen the partners' collaboration in AI-enabled research and development. In the initial phase of the collaboration, launched in March 2025, the companies combined Insilico's Pharma.AI platform with Tenacia's data assets and drug-discovery expertise. "The program focused on developing small-molecule inhibitors with strong blood-brain barrier permeability for CNS treatment is progressing smoothly," the companies said in a statement. "Under the expanded agreement, the companies will leverage generative AI to jointly develop an additional innovative candidate with defined properties for challenging neurological diseases and advance it to the preclinical candidate stage to address differentiated clinical needs." In February, Insilico announced multiple drug discovery collaborations with China Medical System (CMS), an open-platform company that links pharmaceutical innovation and commercialization with product lifecycle management. That partnership focuses on the central nervous system and autoimmune diseases. In January, Insilico unveiled a multi-year R&D collaboration with French-based Servier, which focuses on developing oncology therapies. The deal was valued at up to $888 million. The same month, Insilico partnered with China-based Qilu Pharmaceutical Group to develop novel cardiometabolic disease therapies leveraging Pharma.AI.​ The total contract value approached $120 million, and the partnership includes development and commercialization milestone payments, as well as royalties based on sales. Insilico is not a U.S. public company but began trading on the Hong Kong Stock Exchange in December. It completed its IPO under the ticker 3696.HK on Dec. 30, 2025, and raised around HKD 2.28 billion ($290 million), making it one of the largest biotech IPOs in Hong Kong in 2025. The content above comes from the network. if any infringement, please contact us to modify.

This AI-centric partnership deepens ties between Eli Lilly and Insilico Medicines. Credit: Jiw Ingka / Shutterstock.com. Eli Lilly is joining forces with artificial intelligence (AI)-powered biotech, Insilico Medicine, in a drug discovery and development agreement worth up to $2.75bn. Through this collaboration, Lilly will use Insilico’s Pharma.AI platform to support its novel oral drug discovery and development efforts spanning several disease areas. As per the terms of the deal, Lilly will own the exclusive global development and commercialisation rights to any of the candidates created from this agreement. Insilico will also lend Lilly a hand in the development process, as the biotech will help to progress multiple R&D programmes associated with targets picked by Lilly. In exchange for the use of Insilico’s services, Lilly will hand over $115m upfront, while committing itself to paying out up to $2.63bn in development, regulatory and commercial milestone payments tied to the preclinical candidates produced. Insilico will also be eligible to receive tiered royalties on any future sales. In a 29 March statement, Insilico noted that the pair would primarily focus on diseases with high unmet needs, though no further details on the specifics of the collaboration were disclosed. This pact deepens Lilly’s connection with Insilico, as the pair have previously inked several AI-focused deals, including a research agreement worth more than $100m in November 2025. Lilly and Insilico first collaborated in 2023 through an AI licensing agreement. Lilly backs AI-driven dealmaking approach Lilly’s pact with Insilico comes amid a flurry of dealmaking activity by the Indiana-based pharma, as it looks to further stock its pipeline with profits generated from the burgeoning commercial success of its tirzepatide franchise. Lilly has signed several deals in recent months that centre around AI, which the company is embracing to speed up development timelines and discover new drugs. As per GlobalData’s Pharmaceutical Intelligence Center, Eli Lilly signed 16 AI-focused deals in 2025, including seven licensing agreements worth more than $2bn in value. These include an AI-driven RNA therapy deal with Creyon Bio worth more than $1bn, which the pair signed back in April 2025. GlobalData is the parent company of Pharmaceutical Technology . Outside of the AI realm , Eli Lilly has also acquired multiple companies in 2026 thus far, having handed over $1.2bn and $2.4bn to acquire inflammatory specialist, Ventyx Biosciences and in vivo cell therapy developer, Orna Therapeutics , in January and February 2026, respectively. Currently, the company is riding high on the commercial victories of Zepbound and Mounjaro in the obesity and type 2 diabetes markets, which have pushed the pharma giant into the $1trn market cap club primarily inhabited by tech players like Apple, Meta and NVIDIA. Across the wider pharma sphere, several companies are also investing in AI to power the next generation of pipeline development. This includes UK-Swedish pharma company, AstraZeneca, which agreed to acquire Massachusetts-quartered Modella AI to support drug development within its oncology pipeline back in January 2026.